Navigation Links
Lexicon Develops Antibodies That Lower Triglycerides and,Cholesterol as Potential New Therapy for Heart Disease

nt and chief scientific officer at Lexicon and an author on the paper. "The research our team published today may be an important first step in the development of a new treatment for severe cardiovascular disease, which continues to be the leading cause of death in the United States."

Earlier this year, researchers at the University of Texas Southwestern Medical Center in Dallas, the Institute of Molecular Medicine at the University of Texas Health Science Center in Houston, and other collaborating institutions found that individuals with a mutated ANGPTL4 gene have significantly lower triglyceride levels and higher levels of HDL cholesterol (or "good" cholesterol).(1) These results from human genetic studies further support Lexicon's therapeutic strategy based on original observations made using animal models.

Lexicon scientists discovered ANGPTL4's utility as a potential cardiovascular disease target as part of its Genome5000(TM) program, and the discovery was selected for inclusion in its collaboration with Genentech, Inc. The collaboration with Genentech was initiated in December 2002 to discover the functions of secreted proteins and potential antibody targets identified through Genentech's Secreted Protein Discovery Initiative (also referred to as the SPDI program), and was expanded in November 2005 to include the advanced research, development and commercialization of new biologic drugs. Under the collaboration, Lexicon has the right to develop and commercialize biotherapeutic drugs for up to six targets. Genentech retains an option on the potential development and commercialization of the biotherapeutic drugs that Lexicon develops from the collaboration under a cost and profit sharing arrangement. ANGPTL4, referred to internally as LG842, is one of two targets already chosen by Lexicon for internal development. Lexicon has already generated versions of ANGPTL4 monoclonal antibodies that are currently in preclinical evaluation to identify a pote
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune Deficiency
2. Lexicon-Genentech Collaboration Yields Potential Therapeutic Targets
3. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
4. Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
7. Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers
8. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
9. Large Study Shows that Presence of Neutralizing Antibodies Did Not Predict Clinical Response to Betaseron Treatment
10. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
11. Point of Care Strep Tests Speed Treatment, Lower Costs
Post Your Comments:
(Date:9/2/2014)...  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) today ... company at the Morgan Stanley Global Healthcare Conference in ... Tuesday September 9, 2014 , Presentation time: 5:15 p.m. ... archive of this presentation will be available at http://ir.avanir.com ... Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing ...
(Date:9/2/2014)... 2014  Edison Nation Medical, the premier healthcare ... American Association for Respiratory Care ( AARC ), ... Edison Nation Medical, which brings 12+ years experience ... their innovation ideas, will work with AARC to ... 50,000 respiratory therapists in bringing their product innovation ...
(Date:9/2/2014)... Today, Analysts Review released its ... ), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR ), ... (NYSE: SNY ) and GlaxoSmithKline plc (NYSE: ... publication. To reserve complementary membership, limited openings are available ... Reports ,WellPoint Inc. (WellPoint) posted on the Events and ...
Breaking Medicine Technology:Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 2Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 4Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 5Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 6
... 2011 Fuisz ( www.fuisz.com ) today announced the ... Permitting Stage Door Access to On-Line Vendor Information"). ... "This patent covers a system that allows a customer ... a product supplier database through the on-line vendor,s system ...
... 15, 2011 Cardium Therapeutics (NYSE Amex: ... from the Russian Ministry of Health and Social Development ... Company,s Generx™ (alferminogene tadenovec, Ad5FGF-4) biologic product candidate.  Generx ... for the potential treatment of myocardial ischemia due to ...
Cached Medicine Technology:Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 2Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 3Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 4Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 5Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 6Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 7
(Date:9/2/2014)... in California, the percentage undergoing a double mastectomy increased ... not associated with a lower risk of death than ... the September 3 issue of JAMA . The ... one breast was associated with a higher risk of ... , Randomized trials have demonstrated similar survival for patients ...
(Date:9/2/2014)... cancer cells can lay the groundwork for their own ... vessels to send out tumor-welcoming signals, according to a ... the Sept. 2 issue of Nature Communications , ... increased levels of so-called signaling molecules released by breast ... in the lungs and lymph nodes to produce proteins ...
(Date:9/2/2014)... Medex Analytic Services is delighted to ... Coral Springs, Fla. due to their greater than forecasted ... for the 2014 year by distinguishing Medex in the ... a higher level of service and professionalism in the ... the industry has responded.” , The location of the ...
(Date:9/2/2014)... (PRWEB) September 03, 2014 Operators in ... to millions of people annually, arranging care and counsel ... and private enterprises are expected to derive $39.4 billion ... donations and private income. Over the five years through ... annualised rate of 6.6%, including growth of 4.1% in ...
(Date:9/2/2014)... new studies further confirm the health benefits of breast-feeding. ... a lower risk of ear, throat and sinus infections ... similar trend when it comes to allergies. The ... immediate newborn period," said Dr. Jennifer Wu, an obstetrician-gynecologist ... was not involved in the new studies. The ...
Breaking Medicine News(10 mins):Health News:Increase seen in use of double mastectomy 2Health News:Increase seen in use of double mastectomy 3Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2
... of "color-coded" laboratory mice are providing researchers with a ... and monitor the cellular immune responses of transplanted tissue ... in the June issue of Nature Medicine , ... are a key consideration in developing strategies to improve ...
... release is available in Spanish . , ... , from the Department of Physiology of the University ... Castillo Garzn . To carry out this project, the researcher ... and Assessment of Nutritional Status of Spanish Adolescents) and HELENA ...
... ... Cancer joins Cyberknife of Long Island , ... (PRWEB) May 27, 2010 -- Cyberknife of Long Island treats tumors ... Accuray offers unprecedented capabilities and renewed hope to prostate cancer patients. Cyberknife ...
... sex, still urged, experts say, , THURSDAY, May 27 (HealthDay ... for transmitting the virus to their partners by 90 percent ... Antiretroviral drug therapy helps reduce HIV levels in the infected ... to others. The drugs are commonly taken in the United ...
... in end-stage cardiac patients has a significantly lower risk for ... researchers at Henry Ford Hospital in Detroit. Known as ... HeartMate ,is much smaller than the first and uses a ... itself, to continually push blood through the body. Its predecessor ...
... ... no longer have access to per incident technical support services , ... (PRWEB) May 27, 2010 -- In a recent announcement ... Avaya maintenance agreement will no longer have access to per incident technical support services which ...
Cached Medicine News:Health News:Color-coded tracking method helps scientists analyze outcomes of newly transplanted tissue 2Health News:Color-coded tracking method helps scientists analyze outcomes of newly transplanted tissue 3Health News:Researchers validate a new test for assessing children's and teenagers' fitness to prevent morbidity 2Health News:Cyberknife of Long Island Destroys Prostate Cancer Non-Invasively Using Radiosurgery 2Health News:Cyberknife of Long Island Destroys Prostate Cancer Non-Invasively Using Radiosurgery 3Health News:Anti-HIV Drugs May Help Prevent Spread of Virus 2Health News:Henry Ford Hospital study: Fewer infections with new heart-pump implant 2Health News:Avaya Announces End of Support to Non Maintenance Customers 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: